Paul Hastings LLP advised Leerink Partners and Stifel as joint bookrunning managers in connection with Evolus, Inc.’s underwritten offering of 3,554,000 shares of common stock at $14.07 per share.  The company has granted the underwriters a 30-day option to purchase up to an additional 533,100 shares of common stock at the underwritten offering price, less underwriting discounts and commissions. Evolus, Inc., (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. 

Partner and Co-head of Equity Capital Markets and Co-chair of the Corporate Life Sciences Group Seo Salimi led the Paul Hastings team, which included associates Lauren Zhang and Adam Swank. 

More details on the transaction can be found here. 

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.